Transdermal patch and topical compositions comprising propylnorapomorphine
First Claim
1. A transdermal patch comprising:
- at least one support film;
an intermediate matrix comprising a pharmaceutical composition; and
a protective release strip, wherein the pharmaceutical composition comprises an active principle selected from one or more components of the group consisting of R(−
)-propylnorapomorphine hydrochloride, S(+)-propylnorapomorphine hydrochloride, derivatives of R(−
)-propylnorapomorphine hydrochloride and derivatives of S(+)-propylnorapomorphine hydrochloride, in pharmaceutically acceptable and effective doses, and further comprising components selected from the group consisting of stabilizers, solubilizers and permeation activators to facilitate the passage of the active principle through skin.
1 Assignment
0 Petitions
Accused Products
Abstract
A pharmaceutical composition is characterized by: an active principle selected from one or more components of the group consisting of R(−)-propylnorapomorphine hydrochloride, S(+)-propylnorapomorphine hydrochloride, derivatives of R(−)-propylnorapomorphine hydrochloride and derivatives of S(+)-propylnorapomorphine hydrochloride, in pharmaceutically acceptable and effective doses, and further comprising components selected from the group consisting of stabilizers, solubilizers and permeation activators to facilitate the passage of the active principle through the skin. A transdermal patch that includes the pharmaceutical composition is also disclosed as well as a method of treatment for Parkinson'"'"'s disease, hemicrania, sexual impotence, and psychotic disorders using the pharmaceutical composition or a transdermal patch that includes the pharmaceutical composition are described.
11 Citations
15 Claims
-
1. A transdermal patch comprising:
- at least one support film;
an intermediate matrix comprising a pharmaceutical composition; and
a protective release strip, wherein the pharmaceutical composition comprises an active principle selected from one or more components of the group consisting of R(−
)-propylnorapomorphine hydrochloride, S(+)-propylnorapomorphine hydrochloride, derivatives of R(−
)-propylnorapomorphine hydrochloride and derivatives of S(+)-propylnorapomorphine hydrochloride, in pharmaceutically acceptable and effective doses, and further comprising components selected from the group consisting of stabilizers, solubilizers and permeation activators to facilitate the passage of the active principle through skin. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- at least one support film;
Specification